¼¼°èÀÇ ³»ºÐºñ ÆéƼµå °Ë»ç ½ÃÀå º¸°í¼­(2025³â)
Endocrine Peptide Test Global Market Report 2025
»óǰÄÚµå : 1704275
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,339,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,163,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,987,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

³»ºÐºñ ÆéƼµå °Ë»ç ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â ¿¬Æò±Õ 9.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 142¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀåÀº ³»ºÐºñ ÆéƼµå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿¬±¸°³¹ß Ȱµ¿ÀÇ ¼ºÀå, »ýȰ½À°üº´ Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ´ëÁßÀÇ ´ç´¢º´ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ³»ºÐºñ °Ë»ç¹ýÀÇ ¹ßÀü, Á¦Ç° ±â¼ú ¹ßÀü, ½Å±Ô °Ë»ç ¼Ö·ç¼Ç °³¹ßÀ» À§ÇÑ R&D Ȱµ¿ Ȱ¼ºÈ­, Á¦Ç° ½ÂÀÎ ¼ö Áõ°¡, ¿¹¹æÀû °Ç°­°ü¸®·ÎÀÇ Àüȯ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

´ç´¢º´ À¯º´·ü Áõ°¡´Â ³»ºÐºñ ÆéƼµå °Ë»ç ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´Àº Ç÷´ç(Æ÷µµ´ç)ÀÇ »ó½ÂÀ» Ư¡À¸·Î ÇÏ´Â ´Ù¾çÇÑ º´Å¸¦ ¸»ÇÕ´Ï´Ù. ´ç´¢º´ ȯÀÚ Áõ°¡´Â ½Ä½À°ü Àå¾Ö, ÁÂ½Ä »ýȰ½À°ü, À¯ÀüÀû ¿äÀÎ, °í·ÉÈ­ µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Çì¸ð±Û·Îºó A1c, °øº¹ Ç÷´ç, C ÆéƼµå °Ë»ç¸¦ Æ÷ÇÔÇÑ ³»ºÐºñ ÆéƼµå °Ë»ç´Â ´ç´¢º´ Áø´Ü, Æ÷µµ´ç ¼öÄ¡ ¸ð´ÏÅ͸µ, Àν¶¸° »ý»ê ¹× ¹Î°¨µµ Æò°¡¿¡ »ç¿ëµË´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 6¿ù ¿µ±¹ Á¤ºÎ ±â°üÀÎ ±¹¹Îº¸°Ç¼­ºñ½º(NHS)´Â 40¼¼ ¹Ì¸¸ÀÇ ´ç´¢º´ Áø´ÜÀ» ¹ÞÀº »ç¶÷ÀÇ ¼ö°¡ 2022³â 17¸¸ 3,166¸í¿¡¼­ 2023³â 21¸¸ 6,440¸íÀ¸·Î Å©°Ô Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ °°Àº Å« Æø Áõ°¡´Â ÀþÀº ÃþÀÇ ´ç´¢º´ ȯÀÚ Áõ°¡¶ó´Â ¿ì·Á½º·¯¿î Ãß¼¼¸¦ º¸¿©ÁÝ´Ï´Ù. µû¶ó¼­ ´ç´¢º´ À¯º´·ü Áõ°¡´Â ³»ºÐºñ ÆéƼµå °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

³»ºÐºñ ÆéƼµå °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀº Á¤È®¼º, ¹Î°¨µµ, ¼Óµµ¸¦ ³ôÀ̱â À§ÇØ ¸é¿ªÃøÁ¤ °Ë»ç ½Ã½ºÅÛÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Ç×ü¸¦ »ç¿ëÇÏ¿© Ç÷¾×À̳ª ¼Òº¯ »ùÇÿ¡¼­ ƯÁ¤ ÆéƼµå¸¦ °ËÃâÇϰí Á¤·®È­ÇÏ¿© ÀÇ·á Àü¹®°¡¿¡°Ô È£¸£¸ó ¼öÁذú ³»ºÐºñ ±â´É¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Áö¸à½º ÇïÆ¼´Ï¾î½º´Â 2023³â 7¿ù ³»ºÐºñ ÆéƼµå ºÐ¼®À» Æ÷ÇÔÇÑ ¸é¿ªÃøÁ¤ ¹× ÀÓ»óÈ­ÇÐ °Ë»ç¸¦ À§ÇÑ ÄÄÆÑÆ®ÇÑ ½Ã½ºÅÛÀÎ Atellica CI Analyzer¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Atellica CI Analyzer´Â ³­¼Ò ¿¹ºñ·Â Æò°¡¸¦ À§ÇÑ Ç׹ķ¯ È£¸£¸ó(AMH), ÀÚ°£ÀüÁõ ¿¹Èĸ¦ À§ÇÑ sFlt-1, PlGF µî »ý½Ä ³»ºÐºñÇÐ ¸Þ´º°¡ Ư¡À̸ç, ½Ã°£´ç ÃÖ´ë 1,000°ÇÀÇ °Ë»ç°¡ °¡´ÉÇÑ Atellica CI Analyzer´Â ½Å¼ÓÇϰí ÀϰüµÈ °íǰÁúÀÇ °á°ú¸¦ °Ë»ç½ÇÀÌ º¯È­ÇÏ´Â °Ë»ç ¼ö¿ä¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º ¹× °æ±âȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The endocrine peptide test is a diagnostic procedure used to assess levels of specific peptides in blood or urine, crucial for monitoring the endocrine system's function and detecting related disorders. It primarily focuses on measuring peptide hormones in blood to diagnose and track endocrine disorders.

Key tests in the endocrine peptide market include dehydroepiandrosterone sulfate (DHEAS), progesterone, luteinizing hormone, thyroid prolactin, estradiol, human chorionic gonadotropin, thyroid-stimulating hormone, among others. The DHEAS test specifically measures DHEAS levels in the bloodstream. Technologies employed include mass spectroscopy, immunoassay, chromatography, nucleic acid-based methods, and others. End users include clinics, healthcare centers, hospitals, and commercial laboratories.

The endocrine peptide test market research report is one of a series of new reports from The Business Research Company that provides endocrine peptide test market statistics, including the endocrine peptide test industry global market size, regional shares, competitors with endocrine peptide test market share, detailed endocrine peptide test market segments, market trends, and opportunities, and any further data you may need to thrive in the endocrine peptide test industry. These endocrine peptide test market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The endocrine peptide test market size has grown strongly in recent years. It will grow from $9.11 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing government spending, rising prevalence of diabetes, decreasing level of immunity in people across the world, high risk of contracting any chronic diseases, and rising government initiatives.

The endocrine peptide test market size is expected to see strong growth in the next few years. It will grow to $14.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for endocrine peptide test, growth in research and development activities, rise in number of lifestyle diseases, increasing geriatric population, and rising prevalence of diabetes amongst the masses. Major trends in the forecast period include advancement in the endocrine testing method, advancements in product technologies, increasing research and development activities to develop novel testing solutions, growing number of product approval, and shift towards preventive healthcare.

The growing prevalence of diabetes is expected to drive the expansion of the endocrine peptide test market. Diabetes refers to a range of conditions characterized by elevated blood sugar (glucose) levels. The rise in diabetes cases is attributed to factors such as poor diets, sedentary lifestyles, genetic factors, and an aging population. Endocrine peptide tests, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are used to diagnose diabetes, monitor glucose levels, and evaluate insulin production and sensitivity. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported a notable increase in the number of individuals under 40 diagnosed with diabetes, rising from 173,166 in 2022 to 216,440 in 2023. This significant increase highlights the concerning trend of rising diabetes cases among younger individuals. Therefore, the increasing prevalence of diabetes is fueling the growth of the endocrine peptide test market.

Leading companies in the endocrine peptide test market are advancing immunoassay testing systems to enhance accuracy, sensitivity, and speed. These systems employ antibodies to detect and quantify specific peptides in blood or urine samples, providing healthcare professionals with essential insights into hormone levels and endocrine function. For example, Siemens Healthineers introduced the Atellica CI Analyzer in July 2023, a compact system capable of immunoassay and clinical chemistry testing, including endocrine peptide assays. It features a reproductive endocrinology menu with tests such as anti-Mullerian hormone (AMH) for ovarian reserve assessment and sFlt-1 and PlGF for preeclampsia prognosis. With a capacity of up to 1000 tests per hour, the Atellica CI Analyzer ensures rapid and consistent delivery of high-quality results, supporting laboratories in meeting evolving testing demands.

In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics to bolster its portfolio in pediatric endocrinology and men's health. Jatenzo, a testosterone replacement therapy, complements Tolmar's specialty pharmaceutical products, enhancing their offerings for individuals with endocrine disorders. Clarus Therapeutics, known for developing therapies in this field, facilitated the acquisition, expanding Tolmar's market presence and therapeutic capabilities.

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the endocrine peptide test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrine peptide test market includes revenues earned by entities by providing services such as diagnostic testing, laboratory analysis, research studies, and clinical evaluations. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine peptide test market also includes sales of diagnostic kits, reagents, testing instruments, and laboratory equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endocrine Peptide Test Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endocrine peptide test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for endocrine peptide test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endocrine peptide test market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Endocrine Peptide Test Market Characteristics

3. Endocrine Peptide Test Market Trends And Strategies

4. Endocrine Peptide Test Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Endocrine Peptide Test Growth Analysis And Strategic Analysis Framework

6. Endocrine Peptide Test Market Segmentation

7. Endocrine Peptide Test Market Regional And Country Analysis

8. Asia-Pacific Endocrine Peptide Test Market

9. China Endocrine Peptide Test Market

10. India Endocrine Peptide Test Market

11. Japan Endocrine Peptide Test Market

12. Australia Endocrine Peptide Test Market

13. Indonesia Endocrine Peptide Test Market

14. South Korea Endocrine Peptide Test Market

15. Western Europe Endocrine Peptide Test Market

16. UK Endocrine Peptide Test Market

17. Germany Endocrine Peptide Test Market

18. France Endocrine Peptide Test Market

19. Italy Endocrine Peptide Test Market

20. Spain Endocrine Peptide Test Market

21. Eastern Europe Endocrine Peptide Test Market

22. Russia Endocrine Peptide Test Market

23. North America Endocrine Peptide Test Market

24. USA Endocrine Peptide Test Market

25. Canada Endocrine Peptide Test Market

26. South America Endocrine Peptide Test Market

27. Brazil Endocrine Peptide Test Market

28. Middle East Endocrine Peptide Test Market

29. Africa Endocrine Peptide Test Market

30. Endocrine Peptide Test Market Competitive Landscape And Company Profiles

31. Endocrine Peptide Test Market Other Major And Innovative Companies

32. Global Endocrine Peptide Test Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endocrine Peptide Test Market

34. Recent Developments In The Endocrine Peptide Test Market

35. Endocrine Peptide Test Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â